Docrates cancer center

Helsinki 180

2 studies enrolling now · 10 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, Advanced Solid Tumors, Anal Carcinoma, Basal Cell Carcinoma (Unresectable or Metastatic), Biliary Tract Cancer, Cervical Cancer, Clear Cell Ovarian or Endometrial Carcinoma, Cutaneous Squamous Cell Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L), Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

Studies at this site

• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — Recruiting now
• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer — Recruiting now
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors — Stopped early
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 — Running, not enrolling
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors — Completed
• Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer — Stopped early